Drugs / anti-EGFR-bispecific antibody armed activated T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04137536 | Oct 2019 → Apr 2027 expected | pancreatic adenocarcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-EGFR-bispecific antibody armed activated T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04137536 ↗ |
| Modality | Cell therapy | “We generated ex vivo armed T cells (EATs)” PMID 33986124 ↗ May 2021 |
| Target | EGFR | “anti-EGFR-bispecific antibody armed activated T-cells” NCT04137536 ↗ |